Stock HLS HLS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Market Closed - Toronto S.E.
Other stock markets
 02:10:40 2024-05-30 pm EDT 		5-day change 1st Jan Change
3.72 CAD -7.00% Intraday chart for HLS Therapeutics Inc. -4.12% -5.82%
May. 28 HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study MT
May. 28 HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study
MT
New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment
AQ
HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment
CI
Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance
MT
HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
HLS Therapeutics Brief: Q1 2024 revenue was US$12.5 million, Adjusted EBITDA was $2.7 million and cash from operations was $0.8 million
MT
HLS Therapeutics Announces Q1 2024 Financial Results
AQ
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024
CI
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call
AQ
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
AQ
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA
CI
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
AQ
Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update
MT
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022
MT
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million
MT
HLS Therapeutics Announces Fiscal 2023 Financial Results
AQ
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HLS Stock
  4. News HLS Therapeutics Inc.